AND017

Phase 2Small molecule

KKind Pharmaceuticals LLC

AND017 is one of 152 small molecule programs targeting Anemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

ThalassemiaActive, not recruiting

AnemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

ThalassemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

AND017

KKind Pharmaceuticals LLC

Phase 2

3 2

Uloric

Takeda

Preclinical

3 3

Glucotrol

Pfizer

Preclinical

1 4

Vemlidy

Gilead

Preclinical

1 5

Flomax

Activase

PROCRIT

1 8

Genotropin

EMD Serono

Preclinical

1 9

Sodium Valproate

AstraZeneca

Preclinical

4 10

Tradjenta

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Myelodysplastic Syndrome

NCT06304103

Q3 2027

Phase 3Recruiting

Chronic Kidney Disease

NCT07487727

Phase 2Recruiting

Thalassemia

NCT06302491

Q2 2028

Phase 2Not yet recruiting

Chemotherapy

NCT06075030

Q3 2028

Phase 2Not yet recruiting

Anemia

NCT06075043

Clinical

Trials by Indication[1]

Chronic Kidney Disease3 trials

A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

Recruiting·KKind Pharmaceuticals LLC·Phase 3·NCT07487727·240 enrolled

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

Completed·KKind Pharmaceuticals LLC·Phase 2·NCT05035641·113 enrolled

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Completed·KKind Pharmaceuticals LLC·Phase 2·NCT05265325·175 enrolled

Myelodysplastic Syndrome1 trial

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Recruiting·KKind Pharmaceuticals LLC·Phase 2·NCT06304103·63 enrolled

ART1 trial

A Food-Effect Study of AND017 in Healthy Participants

Completed·KKind Pharmaceuticals LLC·Phase 1·NCT04712500·14 enrolled

Thalassemia1 trial

A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

Recruiting·KKind Pharmaceuticals LLC·Phase 2·NCT06302491·64 enrolled

Anemia1 trial

A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

Not yet recruiting·KKind Pharmaceuticals LLC·Phase 2·NCT06075043·36 enrolled

2 more indications

Chemotherapy1 trial

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Not yet recruiting·KKind Pharmaceuticals LLC·Phase 2·NCT06075030·36 enrolled

Unspecified1 trial

A Dose-escalation Study of AND017 in Healthy Subjects

Completed·KKind Pharmaceuticals LLC·Phase 1·NCT04751539·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for AND017. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AND017 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AND017. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kind Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKind Pharmaceuticals LLC

AND017

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Chronic Kidney Disease3 trials

Myelodysplastic Syndrome1 trial

ART1 trial

Thalassemia1 trial

Anemia1 trial

Chemotherapy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News